Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

Vosaroxin is an anti-cancer quinolone-derived DNA topoisomerase II inhibitor. We investigated vosaroxin with decitabine in patients ≥60 years of age with newly diagnosed acute myeloid leukemia (n=58) or myelodysplastic syndrome (≥10% blasts) (n=7) in a phase II non-randomized trial. The initial 22 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Daver, Naval, Kantarjian, Hagop, Garcia-Manero, Guillermo, Jabbour, Elias, Borthakur, Gautam, Brandt, Mark, Pierce, Sherry, Vaughan, Kenneth, Ning, Jing, Nogueras González, Graciela M., Patel, Keyur, Jorgensen, Jeffery, Pemmaraju, Naveen, Kadia, Tapan, Konopleva, Marina, Andreeff, Michael, DiNardo, Courtney, Cortes, Jorge, Ward, Renee, Craig, Adam, Ravandi, Farhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622855/
https://www.ncbi.nlm.nih.gov/pubmed/28729302
http://dx.doi.org/10.3324/haematol.2017.168732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622855/
https://www.ncbi.nlm.nih.gov/pubmed/28729302
http://dx.doi.org/10.3324/haematol.2017.168732

Ejemplares similares